VYNE Therapeutics (VYNE)
NASDAQ:VYNE
Top Page
VYNE Therapeutics
(NASDAQ:VYNE)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.59
▲(2.41% Upside)
Action:ReiteratedDate:03/12/26
The score is held down primarily by weak financial performance (minimal revenue, ongoing losses, and heavy cash burn) despite low leverage. Technical signals show mild near-term improvement, and corporate events are mixed with a positive merger/financing offset by Nasdaq compliance risk; valuation remains unattractive due to losses and no dividend.
Positive Factors
Low leverage
A near-zero debt profile reduces interest expense and financial distress risk, offering structural flexibility to prioritize R&D and clinical milestones. For a biotech still developing assets, low leverage preserves options for non-dilutive partnerships or staged financings rather than forced debt-driven measures.
Negative Factors
Heavy cash burn
Consistent, sizable negative operating and free cash flow forces ongoing external financing and increases dilution risk. Structural cash consumption constrains the company’s ability to self-fund multiple clinical programs and makes long-term execution dependent on successful financings or partner milestone payments.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
A near-zero debt profile reduces interest expense and financial distress risk, offering structural flexibility to prioritize R&D and clinical milestones. For a biotech still developing assets, low leverage preserves options for non-dilutive partnerships or staged financings rather than forced debt-driven measures.
Read all positive factors
VYNE Therapeutics (VYNE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$20.53M
Dividend YieldN/A
Average Volume (3M)2.75M
Price to Earnings (P/E)―
Beta (1Y)1.62
Revenue Growth6.29%
EPS Growth7.42%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding33,323,170
10 Day Avg. Volume3,707,448
30 Day Avg. Volume2,746,500
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.89
Price to Sales (P/S)43.53
P/FCF Ratio-0.75
Enterprise Value/Market Cap-0.67
Enterprise Value/Revenue-24.14
Enterprise Value/Gross Profit-24.35
Enterprise Value/Ebitda0.47
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.81
Revenue Forecast (FY)$350.00K
VYNE Therapeutics Business Overview & Revenue Model
Company Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials ...
How the Company Makes Money
VYNE Therapeutics primarily generates revenue through the commercialization of its proprietary products and potential partnerships with larger pharmaceutical companies. The company may earn revenue from product sales once its therapies receive reg...
VYNE Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 570.00K | 501.00K | 424.00K | 477.00K | 931.00K |
| Gross Profit | 547.00K | 501.00K | 424.00K | 477.00K | 931.00K |
| EBITDA | -26.73M | -43.63M | -29.26M | -34.22M | -38.80M |
| Net Income | -26.48M | -39.83M | -28.45M | -23.21M | -73.33M |
Balance Sheet | |||||
| Total Assets | 30.16M | 66.91M | 97.69M | 40.76M | 67.05M |
| Cash, Cash Equivalents and Short-Term Investments | 29.01M | 61.52M | 93.25M | 30.91M | 42.25M |
| Total Debt | 0.00 | 99.00K | 214.00K | 0.00 | 349.00K |
| Total Liabilities | 2.40M | 14.82M | 8.95M | 9.56M | 18.41M |
| Stockholders Equity | 27.77M | 52.09M | 88.73M | 31.20M | 48.64M |
Cash Flow | |||||
| Free Cash Flow | -33.12M | -34.09M | -25.34M | -29.20M | -56.37M |
| Operating Cash Flow | -33.12M | -33.97M | -25.34M | -29.20M | -56.37M |
| Investing Cash Flow | 37.37M | 23.36M | -57.35M | 15.67M | 1.03M |
| Financing Cash Flow | -143.00K | -141.00K | 82.39M | 1.65M | 39.78M |
VYNE Therapeutics Technical Analysis
Positive
0.58
Price Trends
0.58
Positive
0.51
Positive
0.59
Positive
Market Momentum
<0.01
Negative
51.88
Neutral
67.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYNE, the sentiment is Positive. The current price of 0.58 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.58, and below the 200-day MA of 0.59, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.88 is Neutral, neither overbought nor oversold. The STOCH value of 67.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VYNE.
VYNE Therapeutics Risk Analysis
VYNE Therapeutics disclosed 85 risk factors in its most recent earnings report. VYNE Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
VYNE Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $6.85M | -1.38 | -60.33% | ― | 13.30% | 22.70% | |
49 Neutral | $82.75M | -0.65 | -116.86% | ― | -98.25% | 63.05% | |
48 Neutral | $20.53M | -0.94 | -74.15% | ― | 6.29% | 7.42% | |
45 Neutral | $15.85M | -0.53 | -189.72% | ― | ― | 70.57% | |
40 Underperform | $195.30M | -0.36 | -2323.94% | ― | ― | 52.39% |
* Healthcare Sector Average
VYNE
VYNE Therapeutics
0.62
-1.09
-63.98%
KZIA
Kazia Therapeutics
7.30
2.35
47.47%
XBIO
Xenetic Biosciences
2.99
-0.28
-8.56%
KALA
KALA BIO
0.21
-6.36
-96.74%
INAB
IN8bio
1.61
-4.66
-74.32%
VYNE Therapeutics Corporate Events
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
VYNE Therapeutics Granted Nasdaq Extension to Regain Compliance
Negative
Mar 12, 2026
On September 12, 2025, VYNE Therapeutics disclosed that it had fallen out of compliance with Nasdaq’s $1.00 minimum bid price requirement after its shares traded below that threshold for 30 consecutive business days and was given until March...
Business Operations and StrategyDividendsM&A Transactions
VYNE Therapeutics Amends Merger Terms with Yarrow Bioscience
Neutral
Jan 30, 2026
On January 30, 2026, VYNE Therapeutics, its wholly owned subsidiary Yarrow Merger Sub Corp., and Yarrow Bioscience amended their December 17, 2025 merger agreement to refine how equity will be issued to Yarrow stockholders in the planned transacti...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
VYNE Therapeutics Announces Merger with Yarrow Bioscience
Positive
Dec 17, 2025
On December 17, 2025, VYNE Therapeutics and Yarrow Bioscience announced a definitive merger agreement resulting in the creation of a combined entity operating as Yarrow Bioscience, Inc. This merger positions the company to advance Yarrow’s l...
Executive/Board ChangesShareholder Meetings
VYNE Therapeutics Approves Director Elections and Proposals
Neutral
Dec 12, 2025
On December 12, 2025, VYNE Therapeutics Inc. held its annual meeting of stockholders where three proposals were considered. The election of two Class I directors was approved, with Elisabeth Sandoval Little and Steven Basta elected to serve until ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.